This is a working overview of somatotroph, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-23. Anything still debated is marked as such rather than presented as settled.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | N-terminal trans-3-hexenoyl group |
| Approximate mass | About 5.1 kDa | Derived from the peptide sequence |
| Primary target | Pituitary GHRH receptor | Somatotroph cells of the anterior pituitary |
| Downstream marker | IGF-1 | Measured indirectly in circulation |
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Gemini 4 (officially Gemini IV) was the second crewed spaceflight in NASA's Project Gemini, occurring in June 1965. It was the tenth crewed American spaceflight (including two X-15 flights at altitudes exceeding 100 kilometers (62 mi; 54 nmi)). Astronauts James McDivitt and Ed White orbited the Earth 66 times in four days, making it the first US flight to approach the five-day flight of the Soviet Vostok 5. The highlight of the mission was the first space walk by an American, during which White floated free outside the spacecraft, tethered to it, for approximately 23 minutes. The flight also included the first attempt to make a space rendezvous as McDivitt attempted to maneuver his craft close to the Titan II upper stage which launched it into orbit, but this was not successful. The flight was the first American flight to perform many scientific experiments in space, including use of a sextant to investigate the use of celestial navigation for lunar flight in the Apollo program.
Reactive hypoglycemia, postprandial hypoglycemia, or sugar crash is symptomatic hypoglycemia occurring within four hours after a high-carbohydrate meal in people with and without diabetes. The term is not necessarily a diagnosis since it requires an evaluation to determine the cause of the hypoglycemia. The condition is related to homeostatic systems used by the body to control the blood sugar level. It is described as a sense of tiredness, lethargy, irritation, or hangover, although the effects can be lessened if a lot of physical activity is undertaken in the first few hours after food consumption. The alleged mechanism for the feeling of a crash is correlated with an abnormally rapid rise in blood glucose after eating. This normally leads to insulin secretion (known as an insulin spike), which in turn initiates rapid glucose uptake by tissues, either storing it as glycogen or fat, or using it for energy production. The consequent fall in blood glucose is indicated as the reason for the "sugar crash". Another cause might be hysteresis effect of insulin action, i.e., the effect of insulin is still prominent even if both plasma glucose and insulin levels were already low, causing a plasma glucose level eventually much lower than the baseline level. Sugar crashes are not to be confused with the after-effects of consuming large amounts of protein, which produces fatigue akin to a sugar crash, but are instead the result of the body prioritising the digestion of ingested food.
==== Keeping the tradition alive ==== Family members often gather to cook lefse as a group effort because the process is more enjoyable as a traditional holiday activity. This gathering also provides training to younger generations keeping the tradition alive. The Sons of Norway have lodges to teach making lefse to younger generations. A lodge in Vancouver, Washington, uses up to 60 pounds (27 kg) of potatoes to make lefse every month. While lefse used to be eaten as a snack food, it is now more often made in large quantities for such lutefisk dinners. Some professional lefse makers can roll 85 to 100 lefse per hour, or even up to 140.
== Fluorescence == The chain catshark is one of four elasmobranch species shown to possesses biofluorescent properties. The researchers of the study examined the vision of Scyliorhinus retifer using microspectrophotometry and designed a "shark-eye" camera that yielded contrast information on areas where fluorescence is anatomically distributed on the shark. The repeated evolution of biofluorescence in elasmobranchs, coupled with a visual adaptation to detect it; and evidence that biofluorescence creates greater luminosity contrast with the surrounding background, highlights the potential importance of biofluorescence in elasmobranch behavior and biology. The key fluorescent pigments in the chain catshark and the swell shark are a set of brominated kynurenine compounds that appear to be synthesized by the kynurenine pathway starting from 6-bromo-tryptophan. The biochemical origin of 6-bromo-tryptophan in these species is not known.
Sources: en.wikipedia.org
In 1986, due to low prostaglandin H2 product purity from thin-layer chromatography and column chromatography, high-performance liquid chromatography with hexane and isopropanol as solvents was developed as an alternative means of isolating the prostaglandin with 98% purity.
bioassay Any analytical method that measures or qualifies the presence, effect, or potency of a substance within or upon a biological system, either directly or indirectly, e.g. by quantifying the concentration of a particular chemical compound within a sample obtained from living organisms, cells, or tissues, and ideally under controlled conditions that compare a sample subjected to an experimental treatment with an unmanipulated sample, so as to permit inferences about the effect of the treatment upon some measured variable.
=== Amino acid synthesis === Six essential amino acids and three nonessential are synthesized from oxaloacetate and pyruvate. Aspartate and alanine are formed from oxaloacetate and pyruvate, respectively, by transamination from glutamate. Asparagine is synthesized by amidation of aspartate, with glutamine donating the NH4. These are nonessential amino acids, and their simple biosynthetic pathways occur in all organisms. Methionine, threonine, lysine, isoleucine, valine, and leucine are essential amino acids in humans and most vertebrates, meaning that oxaloacetate cannot be converted into any of these aminos. However they can be synthesizers in bacteria via biosynthetic pathways that are complex and interconnected.
==== Background ==== In spring 1985 Heseltine displayed little interest in Westland helicopters when approached by Tebbit (then Secretary of State for Trade and Industry) at the time of Alan Bristow's bid for the company, as plenty of American helicopters were available to meet Britain's defence requirements. He attended two meetings about the company's future in June 1985, chaired by Thatcher. Heseltine, who had a poor opinion of Westland's management, was willing to inject £30 million, provided the Treasury contributed half. The idea was not approved. Heseltine took against the new chairman Sir John Cuckney's plan that Westland merge with United Technologies Corporation, of which the US company Sikorsky was a subsidiary, after realising that Westland would probably become responsible for assembling the Sikorsky UH-60 Black Hawk helicopter, which the Ministry of Defence would then be under great pressure to buy, whereas he preferred Westland to go into receivership so that GEC and British Aerospace could buy the viable parts of the business. In mid-October Heseltine suggested a European consortium (which would include French Aérospatiale, German MBB and Italian Agusta). The new Trade and Industry Secretary Leon Brittan at first urged Thatcher to consider a European option (Heseltine later said Brittan preferred this option, although Brittan denied this). The Government was officially neutral (i.e. arguing that it was a matter for Westland directors and shareholders) but by November Heseltine was pushing the European option hard.
== Genetics == Fibrous protein, long filamentous protein molecule that forms one of the two main classes of tertiary structure protein Fusion protein, protein created through genetic engineering from two or more proteins Globular protein, one of the two main protein classes Protein family, group of evolutionarily related proteins Protein methods, techniques used to study proteins Protein subunit, single protein molecule that assembles with other protein molecules to form a multimeric or oligomeric protein Regulatory protein, term used in genetics to describe a protein involved in regulating gene expression
Sources: en.wikipedia.org
== 2009 settlement for off-label uses promotions == On September 2, 2009, the United States Department of Justice fined Pfizer $2.3 billion after one of its subsidiaries, Pharmacia & Upjohn Company, pleaded guilty to marketing four drugs, including Bextra, "with the intent to defraud or mislead." Pharmacia & Upjohn admitted to criminal conduct in the promotion of Bextra, and agreed to pay the largest criminal fine ever imposed in the United States for any matter, $1.195 billion. A former Pfizer district sales manager was indicted and sentenced to home confinement for destroying documents regarding the illegal promotion of Bextra. In addition, a regional manager pleaded guilty to distribution of a misbranded product, and was fined $75,000 and 24 months on probation. The remaining $1 billion of the fine were paid to resolve allegations under the civil False Claims Act case and is the largest civil fraud settlement against a pharmaceutical company. Six whistleblowers were awarded more than $102 million for their role in the investigation. Former Pfizer sales representative John Kopchinski acted as a qui tam relator and filed a complaint in 2004 outlining the illegal conduct in the marketing of Bextra. Kopchinski was awarded $51.5 million for his role in the case because the improper marketing of Bextra was the largest piece of the settlement at $1.8 billion.
29 September Ekranoplan - the Caspian Sea Monster, about the Caspian Sea Monster and ground-effect vehicles; the US accidentally discovered the Ekranoplan in 1970 by the Defense Intelligence Agency; the vehicle was 300 ft long, and 540 tonnes, and twice as big as the B-52; the Soviets called it a 'prototype ship'; the Alekseyev Central Hydrofoil Design Bureau was in Nizhny Novgorod; Igor Vasilevsky and Vladimir Kirillovikh, the chief designer; the company invented the hydrofoil in the late 1950s, winning the Lenin Prize in 1957; hydroaerodynamics engineer Kirril Rozhdestvensky; Victor Dygalo; construction of the KM began in 1963, first tested in October 1966, flown by Vladimir Loginov, reaching 350 mph; designer Dmitri Sinitsyn; Ivan Kapitanets, and its military version; designer Vladimir Bulanov; Günther Jörg of Germany; the possible Spasatel; the Naval Air Warfare Center at Naval Air Station Patuxent River. Narrated by Heather Couper, produced by Grant McKee, directed by Hamish Barbour, made by Ideal World and the Discovery Channel 6 October Homicide in Kennewick, about Kennewick Man, investigated by Jim Chatters; on 6 July 1996 evidence was found; forensic anthropologist Katie Macmillan; anthropological geneticist David Smith of University of California, Davis; forensic anthropologist Doug Owsley; Stephen McNallen of the Asatru Folk Assembly; Samuel George Morton; the Ainu people of Japan. Produced by Eve Kay, directed by Mark Halliley, made by RDF Television with the Discovery Channel
== Toxicity == The Pompilidae family of spider wasps is known for its powerful and painful sting that is used to paralyse arachnids. Social wasps readily attack any threat to their queen and colony and are the only type of insects responsible for medically significant incidents with humans. However, PMTXs are produced by solitary spider wasps and since solitary wasps do not have a colony to defend, humans normally will not be stung by these wasps. PMTX is not listed by IARC, which suggests that there is no indication of carcinogenicity for humans, other information about the effects of PMTX on humans is currently not available. However, it is thought that it won't have a big impact on humans due to the difference in neurological setup between humans and arachnids. What is known is that being stung by a spider wasp causes local pain and swelling, and some people might have an allergic reaction to the sting which can be dangerous. The symptoms of a spider wasp sting, apart from the allergic reaction, can be treated with a cold compress. Even though humans usually will not be stung by these wasps, there have been scientists that deliberately extensively provoked spider wasps similar to PMTX-producing spider wasps, to have them stung by these animals for research on the pain inflicted by these insects. Because of these individuals, it is known that though spider wasp venom causes paralysis in their arthropod prey, they inflict intense pain that remains for around five minutes onto vertebrates such as humans.
== Pharmacology == Mitragynine pseudoindoxyl is a μ-opioid receptor agonist and δ-opioid receptor antagonist. Animal studies have shown it causes reduced tolerance, withdrawal, and respiratory depression compared to morphine. Respiratory depression is the primary cause of death in the vast numbers of fatalities linked to fentanyl and other opioids. As an atypical analgesic it has a remarkably strong affinity for the MOR (0.087nM), compared with mitragynine at 7.24nM and 7-hydroxymitragynine at 13.5nM (lower figure means stronger binding). This substance has great potential on its own or as a starting point in the development of new and safer opioids. There are currently no documented overdose deaths as a result of usage of the pure substance. However, recreational use of the isolated alkaloid is rare, as it is typically sold for recreational use in a mixture that also contains 7-hydroxymitragynine. This alkaloid may be a biased agonist at the μ-opioid receptor; this may explain the more favorable side effect profile found in some research. However, a 2020 review of these and more recent studies has found issues with some methods originally used to determine ligands to be G protein biased. Oliceridine, thought to be the prototypical G protein biased μ-opioid receptor agonist, along with PZM21 and buprenorphine, were found to be unbiased. Rather, their low intrinsic efficacy interfered with the results of highly amplified assays.
Susineridine (INNTooltip International Nonproprietary Name; developmental code name YZJ-4729) is an atypical μ-opioid receptor (MOR) agonist and opioid analgesic which is under development for the treatment of postoperative pain. It is given intravenously. The drug acts as a selective biased partial agonist of the MOR, with functional selectivity for activation of G protein signaling over β-arrestin2 recruitment. Its mechanism of action and pharmacological activity are said to be similar to those of oliceridine. However, in-vitro findings suggest that susineridine may have a greater degree of G protein bias than oliceridine. The drug produces analgesic effects in multiple animal models of pain and produces less respiratory depression than morphine or oliceridine. The pharmacokinetics of susineridine in humans have been studied. Susineridine was patented and first described in the scientific literature in 2023. It is under development by Shanghai Haiyan Pharmaceutical Technology in China. As of May 2025, the drug is in phase 3 clinical trials for postoperative pain.
Sources: en.wikipedia.org
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.
The N-terminal modification reduces cleavage by circulating peptidases, so the peptide persists longer than native GHRH. That persistence is the main rationale for the synthetic design. Comparative half-life values in humans are reported in regulatory review documents rather than in general reference literature.
Reductions in visceral adipose tissue have been measured in controlled studies of defined populations. Whether the effect generalizes to other groups and persists after treatment stops is less clear. Longer-term outcome data remain limited.
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.